#tirzepatide

#tirzepatide

Novo Nordisk initially dominated the space with its semaglutide-based drugs, Ozempic for diabetes and Wegovy for obesity, securing a strong foothold in both markets. However, Eli Lilly has since pulled ahead with tirzepatide - marketed as Mounjaro for diabetes and Zepbound for weight loss. The drug's dual GLP-1/GIP receptor mechanism delivers superior weight loss - around 20% in trials compared to semaglutide's 14% - propelling Lilly into the market leadership position.

Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts. These stocks provide rising income and often deliver superior total returns through compounding. Research from Hartford Funds, using Ned Davis Research data from 1973 to 2025, shows companies that grew or initiated dividends in the S&P 500 achieved higher average annual returns with lower volatility than non-payers or cutters. Over long periods, dividend growers and initiators outperformed the equal-weighted S&P 500 and demonstrated resilience in market declines.

Of the 308 who benefited from tirzepatide, 254 (82 percent) regained at least 25 percent of the weight they had lost on the drug by week 88. Further, 177 (57 percent) regained at least 50 percent, and 74 (24 percent) regained at least 75 percent. Generally, the more weight people regained, the more their cardiovascular and metabolic health improvements reversed. Data gaps and potential off-ramps

The study, led by Lisa Beutler, MD, PhD, assistant professor of Medicine in the Division of Endocrinology, Metabolism and Molecular Medicine, improves the understanding of the molecular mechanisms influenced by these drugs and could help refine the development of future targeted therapies for treating diabetes and obesity. Incretin receptor agonists are a class of drugs that mimic the effects of incretin hormones - glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) - to stimulate insulin secretion and regulate blood sugar levels.

Before I explain, I want to clarify that I firmly believe in body autonomy. If someone chooses to take a weight loss medication, they should be able to do so without judgment. I hope all potential users are fully informed about the risks and benefits of these medications and are followed responsibly by medical providers. Ideally, they would also be screened for a current or past eating disorder or any other condition that might contraindicate the use of GLP-1s and GIPs.

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model.